Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Martínez Férez IM, Flores Moreno S, Rodríguez López R. Eficacia y seguridad de los fármacos inmunoreguladores, interferón beta y glatiramero, en la esclerosis múltiple remitente recidivante. [Efficacy and safety of the immunoregulatory drugs interferon beta and glatiramer in the treatment of relapsing remitting multiple sclerosis] Seville: Andalusian Agency for Health Technology Assessment (AETSA). 2013 / 4. 2013 Authors' objectives The general objective:
To evaluate the therapeutic equivalence of interferon beta-1a, beta-1b, and glatiramer in the first-line treatment of patients with relapsing remitting multiple sclerosis.
Specific objectives:
To compare the relative efficacy of the two drugs through direct and indirect comparisons.
To evaluate the relative safety of the two drugs through direct and indirect comparisons. Authors' conclusions High doses of the interferons Rebif and Betaferon result in a greater short-term efficacy in reducing attacks and recurrences than Avonex.
The available evidence does not permit us to reliably estimate the relative efficacy of Rebif as compared to Betaferon.
Copaxone, Rebif, and Betaferon exhibit no significant differences in efficacy in terms of risk of recurrence at 2 years.
Indexing Status Subject indexing assigned by CRD MeSH Humans; Interferon-beta; Multiple Sclerosis, Relapsing-Remitting; Peptides Language Published Spanish Country of organisation Spain English summary An English language summary is available. Address for correspondence Agencia de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Av/ Luis Montoto No 89 CP 41007 Sevilla (Spain) Tel. +34 955 921 581 Fax + 34 955 923 572 Email: aetsa.csalud@juntadeandalucia.es AccessionNumber 32013000640 Date abstract record published 16/09/2013 |